National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2016 (No. 2) (PB 11 of 2016)
2Assessment of patient
Start here
Get a plain-English read of 2
Turn the raw legal text into a practical explanation grounded in National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2016 (No. 2) (PB 11 of 2016).
2 Assessment of patient
For the purpose of subparagraph 1(2) of this Part, the patient has been assessed if the treating medical practitioner has:
(1) documented the following information in the patient’s medical records:
- evidence of chronic hepatitis C infection; and
- evidence of the patient’s hepatitis C virus genotype; and
(2) chosen a regimen in accordance with paragraph 3 of this Part; and
(3) collected the following information for the purposes of the authority application:
- the patient’s hepatitis C virus genotype; and
- whether the patient is:
- cirrhotic; or
- Non-cirrhotic
(4) In this paragraph, evidence of chronic hepatitis C infection is documentation of:
- repeat test results showing antibody to hepatitis C virus (anti-HCV) positive; and
- test result showing hepatitis C virus ribonucleic acid (RNA) positive